STACEY COYLE: Open Payments
NPI 1316585474 · NEW BRIGHTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,643 in 145 payments from 28 companies in 2025. Trend: 2023 $4,121 · 2024 $3,249 · 2025 $2,643
Food & beverage: $2,628Education: $15
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 25 | $404 |
| ABBVIE INC. | 25 | $359 |
| AstraZeneca Pharmaceuticals LP | 9 | $164 |
| Lilly USA, LLC | 9 | $161 |
| GlaxoSmithKline, LLC. | 9 | $155 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $142 |
| Novartis Pharmaceuticals Corporation | 5 | $108 |
| Phathom Pharmaceuticals, Inc. | 5 | $99 |
| Merck Sharp & Dohme LLC | 4 | $99 |
Products named: Wegovy, VRAYLAR, JARDIANCE, REXULTI, Ozempic, CAPLYTA, MOUNJARO, TRELEGY ELLIPTA.
Industry payments across PA — which companies pay providers there.
